Elicio Therapeutics, Inc. (Nasdaq: ELTX) ('Elicio” or the 'Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the ...

Researchers from University of Arizona present a new therapeutic target to shield nerve cells from the damage of ALS.

New research offers fresh hope to patients with colorectal cancer, as advances in liquid biomarker technologies are ...

(NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment ...

Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure ...

Researchers at the University of Bayreuth and Forschungszentrum Jülich have demonstrated that specific light-sensitive ...

Synthetic organizers provide a way to control formation of kidney organoids as more reliable models for studying disease and ...

Scientists have developed Spudcell, an advanced synthetic cell capable of adapting to its environment and learning survival skills, marking a breakthrough in synthetic biology.

Permeasis Therapeutics (“Permeasis”), a biotechnology company developing intracellular biologics enabled by its proprietary Membrane Translocation Domain (MTD) platform announced the publication of ...

Clinical data, regulatory milestones, AI-assisted discovery platforms, and expanding development pipelines are creating a steady stream of catalysts that investors will be watching closely during the ...